Toulouse

Az itteni vizsgálatok

Miről szól a helyszín 36 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek

• Tüdőrák8 vizsgálat
• Amiloidózis3 vizsgálat
• Gyomor- és nyelőcsőrák3 vizsgálat
• Mielóma multiplex3 vizsgálat
• Dermatomyositis and polymyositis (myositis)2 vizsgálat
• Hólyagrák2 vizsgálat
• Krónikus limfoid leukémia (CLL)2 vizsgálat
• Krónikus vesebetegség2 vizsgálat
• Lupus (SLE)2 vizsgálat
• Petefészekrák2 vizsgálat
• Szívelégtelenség2 vizsgálat
• Asztma1 vizsgálat
• és még 10

Fázis

• 3. fázis19 vizsgálat
• 2. fázis5 vizsgálat
• 2/3. fázis3 vizsgálat
• 1/2. fázis2 vizsgálat
• 1. fázis1 vizsgálat

Állapot

• Fut, nem toboroz14 vizsgálat
• Még nem toboroz7 vizsgálat
• Lezárult6 vizsgálat
• Toboroz6 vizsgálat
• Leállították3 vizsgálat

Fő szponzor

• AstraZeneca28 vizsgálat
• Alexion Pharmaceuticals, Inc.4 vizsgálat
• Acerta Pharma BV1 vizsgálat
• Arcus Biosciences, Inc.1 vizsgálat
• Daiichi Sankyo1 vizsgálat
• és még 1

Futó vizsgálatok

• Még nem toboroz

  An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

  NCT07789483· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás

  Contact: Alexion Pharmaceuticals, Inc., Sponsor

• Toboroz

  A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

  NCT07735637· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer

  NCT07851025· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

  NCT07624305· 3. fázis· AstraZeneca· Forrás

  Contact: AstraZeneca Clinical AstraZeneca Clinical

• Toboroz

  Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment

  NCT07691970· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

  NCT07764978· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM

  NCT07608354· 2. fázis· AstraZeneca· Forrás

• Toboroz

  A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

  NCT07391657· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

  NCT07088926· 2. fázis· AstraZeneca· Forrás

• Toboroz

  Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

  NCT07129993· 2/3. fázis· Daiichi Sankyo· Forrás

• Toboroz

  UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance

  NCT06726720· AstraZeneca· Forrás

• Toboroz

  A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

  NCT06455449· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

  NCT06183931· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás

• Toboroz

  A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

  NCT06129864· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

  NCT06109779· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

  NCT06103864· 3. fázis· AstraZeneca· Forrás

  Contact: AstraZeneca Breast Cancer Study Locator Service

• Toboroz

  Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

  NCT06005493· 1/2. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.

  NCT05683977· AstraZeneca· Forrás

• Fut, nem toboroz

  National Acalabrutinib Observational Study

  NCT05437250· AstraZeneca· Forrás

• Fut, nem toboroz

  PASS of Paediatric Patients Initiating Selumetinib

  NCT05388370· AstraZeneca· Forrás

• Fut, nem toboroz

  Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations

  NCT05103605· AstraZeneca· Forrás

• Fut, nem toboroz

  Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

  NCT04784715· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

  NCT02546661· 1. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.

  NCT02734004· 1/2. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

  NCT02477696· 3. fázis· Acerta Pharma BV· Forrás

• Fut, nem toboroz

  Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

  NCT01933932· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

  NCT01843374· 2. fázis· MedImmune LLC· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Mielóma multiplex3 toboroz
• Amiloidózis1 toboroz
• Bronchiectasis1 toboroz
• Dermatomyositis and polymyositis (myositis)1 toboroz
• Fej-nyaki daganatok1 toboroz
• Gyomor- és nyelőcsőrák1 toboroz
• Hasnyálmirigyrák1 toboroz
• Krónikus vesebetegség1 toboroz
• Lupus (SLE)1 toboroz
• Petefészekrák1 toboroz
• Szisztémás szklerózis (szkleroderma)1 toboroz
• Tripla negatív emlőrák1 toboroz
• Tüdőrák1 toboroz

Lezárt vizsgálatok

• Lezárult

  Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

  NCT06750289· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

  NCT06307652· 3. fázis· AstraZeneca· Forrás

• Lezárult

  Retrospective Medical Chart Review Study to Describe the Experience of SLE Patients Treated With Anifrolumab in the Early Access Programs.

  NCT06046534· AstraZeneca· Forrás

• Leállították

  ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

  NCT05746559· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás

• Lezárult

  A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

  NCT05329766· 2. fázis· Arcus Biosciences, Inc.· Forrás

• Leállították

  Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis

  NCT04999020· 2/3. fázis· Alexion Pharmaceuticals, Inc.· Forrás

• Lezárult

  Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%

  NCT04986202· 2/3. fázis· AstraZeneca· Forrás

• Lezárult

  AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT02151981· 3. fázis· AstraZeneca· Forrás

• Lezárult

  A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

  NCT02087423· 2. fázis· AstraZeneca· Forrás